StockNews.AI
APLT
Investopedia
28 days

Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug

1. FDA rejected Applied Therapeutics' application for govorestat in galactosemia. 2. Shares plummeted 75% following the FDA's Complete Response Letter. 3. CEO declared potential benefits of govorestat for patients, citing efficacy data. 4. The company plans to discuss resubmission or appeal with FDA.

4 mins saved
Full Article

FAQ

Why Very Bearish?

The FDA rejection significantly diminishes future product revenue estimates, similar cases have caused stock collapses.

How important is it?

Direct impact on future revenue and product viability makes the rejection critical for investor confidence.

Why Short Term?

The immediate market reactions post-announcement will prevail, although potential recovery may follow appeals.

Related Companies

Related News